Our study showed that in patients with EGFR-mutant lung adenocarcinoma and brain metastases, craniocerebral radiotherapy plays an important role in improving the survival and prognosis, indicating that EGFR-TKIs combined with craniocerebral radiotherapy might be a better therapeutic option for this patient population. The gene discussed is EGFR; the disease is lung adenocarcinoma.